Goldman Sachs Group, Inc. (The) set a €105.00 ($125.00) price objective on Merck KGaA (FRA:MRK) in a report released on Tuesday morning. The brokerage currently has a neutral rating on the healthcare company’s stock.

Other analysts have also issued research reports about the company. Warburg Research set a €116.00 ($138.10) target price on Merck KGaA and gave the company a neutral rating in a report on Tuesday, June 20th. equinet AG set a €112.00 ($133.33) target price on Merck KGaA and gave the company a neutral rating in a report on Monday, June 26th. J P Morgan Chase & Co restated a neutral rating on shares of Merck KGaA in a report on Friday, August 4th. Deutsche Bank AG set a €106.00 ($126.19) target price on Merck KGaA and gave the company a neutral rating in a report on Friday, August 4th. Finally, Kepler Capital Markets set a €128.00 ($152.38) target price on Merck KGaA and gave the company a buy rating in a report on Thursday, June 1st. Thirteen analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Merck KGaA presently has an average rating of Hold and an average target price of €108.38 ($129.02).

Shares of Merck KGaA (FRA MRK) opened at 96.51 on Tuesday. The stock has a market cap of €41.96 billion and a P/E ratio of 25.16. The stock has a 50 day moving average price of €93.46 and a 200-day moving average price of €102.32. Merck KGaA has a 12 month low of €89.00 and a 12 month high of €115.00.

COPYRIGHT VIOLATION WARNING: This story was reported by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/09/23/merck-kgaa-mrk-pt-set-at-105-00-by-goldman-sachs-group-inc-the.html.

About Merck KGaA

.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.